Maricruz Vega1, Manisha Verma2, David Beswick3, Stephanie Bey3, Jared Hossack4, Nathan Merriman3, Ashish Shah5, Victor Navarro2. 1. Einstein Medical Center, 5501 Old York Road, Philadelphia, Pennsylvania, 19141, USA. VegaMari@einstein.edu. 2. Einstein Medical Center, 5501 Old York Road, Philadelphia, Pennsylvania, 19141, USA. 3. Gastroenterology Associates, 4745 Ogletown Stanton Road, Medical Arts Building, Suite 134, Newark, Delaware, 19713, USA. 4. Mid-Atlantic GI Consultants, 537 Stanton Christiana Rd Ste 203, Newark, Delaware, 19713, USA. 5. First State Gastroenterology, 644 South Queen St, Suite 106, Dover, Delaware, 19904, USA.
Abstract
BACKGROUND AND AIM: The population-based incidence rate of drug-induced liver injury (DILI) in the USA is not known. The Drug-Induced Liver Injury Network (DILIN) accrues cases of hepatotoxicity due to medications and herbal and dietary supplements (HDS) from limited geographical areas. The current analysis was an ancillary study of DILIN aimed at determining the annual incidence of DILI in the USA on a population basis, through surveillance in the state of Delaware. METHODS: At the outset of the study, there were 41 gastroenterologists in the state of Delaware and all agreed to participate in surveillance for DILI, which comprised active reporting of suspected cases to the DILIN. The gastroenterologists underwent training in the diagnosis of DILI and were provided with DILIN inclusion criteria. Only cases that met the DILIN laboratory inclusion criteria in 2014 were included in the incidence calculation, and these patients were invited to participate in the DILIN Prospective Study. The number of suspected cases that met inclusion criteria served as the numerator and the 2014 Delaware adult population as the denominator. RESULTS: During 2014, 23 patients were identified by the surveillance network, 20 of whom met DILIN laboratory inclusion criteria, leading to an incidence of 2.7 cases of DILI per 100,000 adult residents [95% confidence interval (CI) 1.5-3.9 per 100,000]. Fourteen subjects agreed to participate in the DILIN; six declined. Among enrolled cases, the mean age was 51 years, 57% were women, and 71% were white. Eight cases were attributed to antibiotics (36%) and other drugs (21%) and six to HDS (43%). The pattern of injury was hepatocellular in all HDS cases, but only 50% of conventional drug cases (p = 0.05), which more commonly presented with eosinophilia (p = 0.47) and higher alkaline phosphatase levels (p = 0.05). Half of patients were jaundiced, none developed liver failure, and all recovered without the need for transplantation. CONCLUSION: Prospective, gastroenterologist-based surveillance for suspected DILI in Delaware yielded an incidence of 2.7 cases per 100,000 adults in 2014; this is the first prospective estimate of DILI for the USA. Because surveillance was limited to subspecialists, the actual incidence of DILI is likely to be higher. These findings provide a benchmark statistic for the epidemiology of DILI in the United States, to be refined with expansion of the surveillance period.
BACKGROUND AND AIM: The population-based incidence rate of drug-induced liver injury (DILI) in the USA is not known. The Drug-Induced Liver Injury Network (DILIN) accrues cases of hepatotoxicity due to medications and herbal and dietary supplements (HDS) from limited geographical areas. The current analysis was an ancillary study of DILIN aimed at determining the annual incidence of DILI in the USA on a population basis, through surveillance in the state of Delaware. METHODS: At the outset of the study, there were 41 gastroenterologists in the state of Delaware and all agreed to participate in surveillance for DILI, which comprised active reporting of suspected cases to the DILIN. The gastroenterologists underwent training in the diagnosis of DILI and were provided with DILIN inclusion criteria. Only cases that met the DILIN laboratory inclusion criteria in 2014 were included in the incidence calculation, and these patients were invited to participate in the DILIN Prospective Study. The number of suspected cases that met inclusion criteria served as the numerator and the 2014 Delaware adult population as the denominator. RESULTS: During 2014, 23 patients were identified by the surveillance network, 20 of whom met DILIN laboratory inclusion criteria, leading to an incidence of 2.7 cases of DILI per 100,000 adult residents [95% confidence interval (CI) 1.5-3.9 per 100,000]. Fourteen subjects agreed to participate in the DILIN; six declined. Among enrolled cases, the mean age was 51 years, 57% were women, and 71% were white. Eight cases were attributed to antibiotics (36%) and other drugs (21%) and six to HDS (43%). The pattern of injury was hepatocellular in all HDS cases, but only 50% of conventional drug cases (p = 0.05), which more commonly presented with eosinophilia (p = 0.47) and higher alkaline phosphatase levels (p = 0.05). Half of patients were jaundiced, none developed liver failure, and all recovered without the need for transplantation. CONCLUSION: Prospective, gastroenterologist-based surveillance for suspected DILI in Delaware yielded an incidence of 2.7 cases per 100,000 adults in 2014; this is the first prospective estimate of DILI for the USA. Because surveillance was limited to subspecialists, the actual incidence of DILI is likely to be higher. These findings provide a benchmark statistic for the epidemiology of DILI in the United States, to be refined with expansion of the surveillance period.
Authors: Einar S Björnsson; Ottar M Bergmann; Helgi K Björnsson; Runar B Kvaran; Sigurdur Olafsson Journal: Gastroenterology Date: 2013-02-16 Impact factor: 22.682
Authors: Victor J Navarro; Huiman Barnhart; Herbert L Bonkovsky; Timothy Davern; Robert J Fontana; Lafaine Grant; K Rajender Reddy; Leonard B Seeff; Jose Serrano; Averell H Sherker; Andrew Stolz; Jayant Talwalkar; Maricruz Vega; Raj Vuppalanchi Journal: Hepatology Date: 2014-08-25 Impact factor: 17.425
Authors: David S Goldberg; Kimberly A Forde; Dena M Carbonari; James D Lewis; Kimberly B F Leidl; K Rajender Reddy; Kevin Haynes; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley; Vincent Lo Re Journal: Gastroenterology Date: 2015-02-28 Impact factor: 22.682
Authors: Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon Journal: Hepatology Date: 2002-08 Impact factor: 17.425
Authors: Francisco J de Abajo; Dolores Montero; Mariano Madurga; Luis A García Rodríguez Journal: Br J Clin Pharmacol Date: 2004-07 Impact factor: 4.335
Authors: Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Dahea You; Lascelles E Lyn-Cook; Daniel M Gatti; Natalie Bell; Philip R Mayeux; Laura P James; William B Mattes; Gary J Larson; Alison H Harrill Journal: Toxicol Sci Date: 2020-06-01 Impact factor: 4.849
Authors: Jay H Hoofnagle; Herbert L Bonkovsky; Elizabeth J Phillips; Yi-Ju Li; Jawad Ahmad; Huiman Barnhart; Francisco Durazo; Robert J Fontana; Jiezhun Gu; Ikhlas Khan; David E Kleiner; Christopher Koh; Don C Rockey; Leonard B Seeff; Jose Serrano; Andrew Stolz; Hans L Tillmann; Raj Vuppalanchi; Victor J Navarro Journal: Hepatology Date: 2021-05-17 Impact factor: 17.425
Authors: Mohamed Kadry Taher; Abdallah Alami; Christopher A Gravel; Derek Tsui; Lise M Bjerre; Franco Momoli; Donald R Mattison; Daniel Krewski Journal: JGH Open Date: 2021-06-04